PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
http://www.peervoice.com
Joe O'Sullivan, MD, PhD, FRCR - Evolving Evidence of Radioligand Therapy in Metastatic Prostate Cancer: A 2023 Clinical Round-Up From Key Congresses
Visit https://www.peervoice.com/RKE860 to view the entire programme with slides. After completing “Joe O'Sullivan, MD, PhD, FRCR - Evolving Evidence of Radioligand Therapy in Metastatic Prostate Cancer: A 2023 Clinical Round-Up From Key Congresses”, participants will be able to: Summarise the most recent clinical data for radioligand therapy (RLT) for the management of men with metastatic castration-resistant prostate cancer (mCRPC); Evaluate how these data add to previous knowledge about the management of mCRPC with RLT; and Discuss the clinical implications of these data in the context of current treatment paradigms for mCRPC.